The Synergism Or Long Duration (SOLD) Study
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Breast Neoplasms
Interventions: DRUG: trastuzumab (9 weeks) + docetaxel|DRUG: trastuzumab (9 weeks) + docetaxel + CEF + trastuzumab (up to 51 weeks)
Sponsor: Finnish Breast Cancer Group